Zacks Investment Research·4d ago
Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?Kodiak's Zenkuda shows promise across three retinal diseases, with positive phase III data and a planned 2026 regulatory filing.
Kodiak Sciences remains a pre-revenue clinical-stage biotech with no approved products, and its financial trajectory is deteriorating: quarterly net losses widened from $43.0M in 2024Q1 to $65.6M in 2026Q2, while cash reserves fell 49% from $245.9M to $125.9M ...
Price trend, volume and key moving averages
Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | -$1.05-9.8% vs -$0.96 | — vs — |
Q2 2026 May 7, 2026 | -$0.94-1.1% vs -$0.93 | — vs — |
Q2 2026 Mar 31, 2026 | -$1.04-2.0% vs -$1.02 | — vs — |
Q4 2025 Nov 13, 2025 | -$1.16-8.4% vs -$1.07 | — vs — |
Kodiak's Zenkuda shows promise across three retinal diseases, with positive phase III data and a planned 2026 regulatory filing.
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company.
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026. Additional presentations include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).
Benchmark KOD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Kodiak Sciences Inc. (KOD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $87.63 | $5.48B | -20.28 | — | — | -149.49% | — | |
| $4.36 | $90.9M | -0.66 | -72.22% | — | — | — | |
| $6.50 | $1.42B | -4.58 | -18.67% | -579.1% | -59.87% | — | |
| $805.02 | $82.93B | 19.41 | 0.99% | 27.86% | 18.49% | — | |
| $6.68 | $345.34M | -1.78 | 104.54% | -112.58% | -220.07% | — | |
| $43.79 | $26.88B | 28.44 | -82.7% | 19.08% | 13.57% | — |
Kodiak Sciences Inc. (KOD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Kodiak Sciences Inc. (KOD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jun 4, 2026·SEC
May 7, 2026·SEC
Get notified when KOD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Kodiak Sciences Inc. (KOD) stock FAQ — growth, dividends, profitability & financials explained
Kodiak Sciences Inc. (KOD) reported a net loss of $242.0M for fiscal year 2025.
Kodiak Sciences Inc. (KOD) has a return on equity (ROE) of -149.5%. Negative ROE indicates the company is unprofitable.
Kodiak Sciences Inc. (KOD) had negative free cash flow of $159.9M in fiscal year 2025, likely due to heavy capital investments.
